AC Immune S.A. (ACIU) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ACIU Revenue Growth
ACIU Revenue Analysis (2014–2025)
As of May 8, 2026, AC Immune S.A. (ACIU) generated trailing twelve-month (TTM) revenue of $3.6 million, reflecting significant decline in growth of -70.3% year-over-year. The most recent quarter (Q4 2025) recorded $338,000 in revenue, down 64.0% sequentially.
Looking at the longer-term picture, ACIU's 5-year compound annual growth rate (CAGR) stands at -25.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $110.5 million in 2019.
When compared to Healthcare sector peers including NRXP, and BIIB (+0.4% YoY), ACIU has underperformed the peer group in terms of revenue growth. Compare ACIU vs NRXP →
ACIU Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ACIUCurrent | $4M | -70.3% | -25.4% | -1927.3% | |
 NRXP | $1M | - | - | -1324.4% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% |
ACIU Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.6M | -86.9% | $3.6M | 100.0% | $-68,863,000 | -1927.3% |
| 2024 | $27.3M | +84.5% | $-35,261,000 | -129.1% | $-52,378,000 | -191.8% |
| 2023 | $14.8M | +276.1% | $-39,805,000 | -268.9% | $-53,624,000 | -362.3% |
| 2022 | $3.9M | - | $3.9M | 100.0% | $-70,847,000 | -1800.4% |
| 2021 | $0 | -100.0% | $0 | - | $-79,010,000 | - |
| 2020 | $15.4M | -86.0% | $-44,056,000 | -285.5% | $-61,260,000 | -397.0% |
| 2019 | $110.5M | +1435.4% | $60.0M | 54.3% | $44.5M | 40.3% |
| 2018 | $7.2M | -64.5% | $-37,083,000 | -515.5% | $-49,550,000 | -688.8% |
| 2017 | $20.3M | -12.7% | $-12,408,000 | -61.3% | $-22,539,000 | -111.3% |
| 2016 | $23.2M | -40.6% | $-2,560,000 | -11.0% | $-10,456,000 | -45.0% |
See ACIU's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACIU Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACIU vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACIU — Frequently Asked Questions
Quick answers to the most common questions about buying ACIU stock.
Is ACIU's revenue growth accelerating or slowing?
ACIU revenue declined -70.3% year-over-year, contrasting with the 5-year CAGR of -25.4%. TTM revenue fell to $4M. This reverses the prior growth trend.
What is ACIU's long-term revenue growth rate?
AC Immune S.A.'s 5-year revenue CAGR of -25.4% reflects the variable expansion pattern. Current YoY growth of -70.3% is below this long-term average.
How is ACIU's revenue distributed by segment?
ACIU reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.